140 related articles for article (PubMed ID: 22899491)
1. Plasmablastic haemato-lymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib.
Dasanu CA; Bauer F; Codreanu I; Padmanabhan P; Rampurwala M
Hematol Oncol; 2013 Sep; 31(3):164-6. PubMed ID: 22899491
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma.
Lipstein M; O'Connor O; Montanari F; Paoluzzi L; Bongero D; Bhagat G
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):E43-6. PubMed ID: 21856550
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation.
Sevilla DW; Gong JZ; Goodman BK; Buckley PJ; Rosoff P; Gockerman JP; Lagoo AS
Am J Clin Pathol; 2007 Dec; 128(6):981-91. PubMed ID: 18024324
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib in plasmablastic lymphoma: a case report and review of the literature.
Saba NS; Dang D; Saba J; Cao C; Janbain M; Maalouf B; Safah H
Onkologie; 2013; 36(5):287-91. PubMed ID: 23689224
[TBL] [Abstract][Full Text] [Related]
5. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features.
Taddesse-Heath L; Meloni-Ehrig A; Scheerle J; Kelly JC; Jaffe ES
Mod Pathol; 2010 Jul; 23(7):991-9. PubMed ID: 20348882
[TBL] [Abstract][Full Text] [Related]
6. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?
Mationg-Kalaw E; Tan LH; Tay K; Lim ST; Tang T; Lee YY; Tan SY
Histopathology; 2012 Dec; 61(6):1214-8. PubMed ID: 23171357
[TBL] [Abstract][Full Text] [Related]
7. MYC and aggressive B-cell lymphomas.
Slack GW; Gascoyne RD
Adv Anat Pathol; 2011 May; 18(3):219-28. PubMed ID: 21490439
[TBL] [Abstract][Full Text] [Related]
8. Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative disorder with evidence suggestive of multiclonal transformability of B cells by Epstein-Barr virus.
Foo WC; Huang Q; Sebastian S; Hutchinson CB; Burchette J; Wang E
Hum Pathol; 2010 Dec; 41(12):1802-8. PubMed ID: 20869749
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
Lin P; Dickason TJ; Fayad LE; Lennon PA; Hu P; Garcia M; Routbort MJ; Miranda R; Wang X; Qiao W; Medeiros LJ
Cancer; 2012 Mar; 118(6):1566-73. PubMed ID: 21882178
[TBL] [Abstract][Full Text] [Related]
10. Plasmablastic lymphoma affecting the lung and bone marrow with CD10 expression and t(8;14)(q24;q32) translocation.
Chuah KL; Ng SB; Poon L; Yap WM
Int J Surg Pathol; 2009 Apr; 17(2):163-6. PubMed ID: 18508845
[TBL] [Abstract][Full Text] [Related]
11. The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement.
Nakamura N; Nakamine H; Tamaru J; Nakamura S; Yoshino T; Ohshima K; Abe M
Mod Pathol; 2002 Jul; 15(7):771-6. PubMed ID: 12118116
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.
Koprivnikar JL; Cheson BD
Future Oncol; 2012 Apr; 8(4):359-71. PubMed ID: 22515439
[TBL] [Abstract][Full Text] [Related]
13. T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.
Gualco G; Weiss LM; Barber GN; Bacchi CE
Hum Pathol; 2010 Sep; 41(9):1238-44. PubMed ID: 20382409
[TBL] [Abstract][Full Text] [Related]
14. Extraoral plasmablastic lymphoma with intravascular component and MYC translocation.
Chapman-Fredricks J; Montague N; Akunyili I; Ikpatt O
Ann Diagn Pathol; 2012 Jan; 16(1):48-53. PubMed ID: 21239197
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Goy A; Younes A; McLaughlin P; Pro B; Romaguera JE; Hagemeister F; Fayad L; Dang NH; Samaniego F; Wang M; Broglio K; Samuels B; Gilles F; Sarris AH; Hart S; Trehu E; Schenkein D; Cabanillas F; Rodriguez AM
J Clin Oncol; 2005 Feb; 23(4):667-75. PubMed ID: 15613697
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic features of B-Cell lineage neoplasms with aberrant expression of CD3: a study of 21 cases.
Oliveira JL; Grogg KL; Macon WR; Dogan A; Feldman AL
Am J Surg Pathol; 2012 Sep; 36(9):1364-70. PubMed ID: 22895269
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood and bone marrow findings in B-cell lymphoma, unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
Ahmad OS; Fishlock K; May P; Kanfer E; Naresh KN
Am J Hematol; 2012 Feb; 87(2):201-2. PubMed ID: 22139902
[No Abstract] [Full Text] [Related]
18. Homogeneous immunophenotype and paucity of secondary genomic aberrations are distinctive features of endemic but not of sporadic Burkitt's lymphoma and diffuse large B-cell lymphoma with MYC rearrangement.
Barth TF; Müller S; Pawlita M; Siebert R; Rother JU; Mechtersheimer G; Kitinya J; Bentz M; Möller P
J Pathol; 2004 Aug; 203(4):940-5. PubMed ID: 15258997
[TBL] [Abstract][Full Text] [Related]
19. [Bortezomib].
Simons S; Scheulen ME; Jaehde U
Dtsch Med Wochenschr; 2006 Feb; 131(5):214-8. PubMed ID: 16440269
[No Abstract] [Full Text] [Related]
20. Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation.
Ruzinova MB; Caron T; Rodig SJ
Am J Surg Pathol; 2010 Jun; 34(6):882-91. PubMed ID: 20442643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
